文献速递血栓与止血

成人原发性免疫性血小板减少症患者交替使用血小板生成素受体激动剂:意大利血液中心回顾性协作调查

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
PubMed 文献 · Am J Hematol · 2017-11-09

该回顾性协作调查评估了在一种TPO-RA治疗失败的成人ITP患者中换用另一种TPO-RA的疗效及临床特征对结局的影响。106/546例患者进行了换药,65%获得、重获或维持短期反应;因疗效问题换药者中57.8%获得/重获反应,因非疗效问题换药者中80%维持反应。长期可评估的49例中27例仍在治疗中反应。

要点

  • 106/546例TPO-RA治疗患者进行了换药,65%获得、重获或维持短期反应。
  • 因疗效问题换药者57.8%获得/重获反应,对第一种TPO-RA无反应者反应率最低。
  • 因非疗效问题换药者80%维持反应,血小板波动者44.4%波动缓解。

核心结论

  • 证实TPO-RA换药有效;一旦对第二种TPO-RA获得反应,该反应似乎持久。

研究设计与样本

  • 回顾性评估在一种TPO-RA治疗失败的ITP患者中序贯使用罗米司亭和艾曲泊帕的疗效及临床特征对结局的影响。
  • 患者分为5类:疗效问题(第一种TPO-RA失败、反应丢失)和非疗效问题(血小板波动、患者偏好、不良事件发生)。
  • 分析了任一种TPO-RA序贯方案在3个月时和末次随访时的结果。

主要发现

  • 106/546例TPO-RA治疗患者进行了换药,65%获得、重获或维持短期反应,与换药顺序、性别或年龄无关。
  • 较低的反应率与既往治疗线数相关;疾病持续时间降低反应概率。
  • 因疗效问题换药的患者与因非疗效问题换药的患者在临床上无差异。
  • 因疗效问题换药者57.8%获得/重获反应,对第一种TPO-RA无反应者反应率最低;因非疗效问题换药者80%维持反应。
  • 血小板波动在44.4%的患者中缓解;49例可评估长期结局的患者中,27例在治疗中反应,16例因非疗效原因停用TPO-RA,仅6例无反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2017. PMID: 28983953. doi:10.1002/ajh.24935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。